Risk of Cardiovascular Events in Patients with Type 2 Diabetes Initiating Oral Antidiabetic Treatments

Study identifier:CV181-099

ClinicalTrials.gov identifier:NCT01086280

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Comparison of Risk of Major Cardiovascular Events Between Patients with Type 2 Diabetes Initiating Saxagliptin and Those initiating Other Oral Antidiabetic Treatments

Medical condition

Diabetes Mellitus, Type 2

Phase

Healthy volunteers

Study drug

Sex

All

Actual Enrollment

113505

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Jan 2010

Primary Completion Date: 01 Dec 2015

Study Completion Date: 01 Dec 2015

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Sept 2016 by AstraZeneca

Collaborators

Bristol Myers Squibb, University of Pennsylvania

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Patients exposed to Saxagliptin	-
Patients exposed to oral antidiabetic drugs (not Saxagliptin)	-

Documents available

BMS Clinical Trials Disclosure
Download
FDA Safety Alerts and Recalls
Download
Investigator Inquiry form
Download
CSR Synopsis
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Clinical Study Information Center

1-877-240-9479

information.center@astrazeneca.com

Investigators

Principal Investigator

Bristol-Myers Squibb

Risk of Cardiovascular Events in Patients with Type 2 Diabetes Initiating Oral Antidiabetic Treatments

Official Title

Medical condition

Phase

Healthy volunteers

Study drug

Sex

Actual Enrollment

Study type

Age

Date

Study design

Verification:

Sponsors

Collaborators

Inclusion Criteria

Exclusion Criteria

Documents available

BMS Clinical Trials Disclosure

FDA Safety Alerts and Recalls

Investigator Inquiry form

CSR Synopsis

Trial Results Summaries

Contacts

Contact

Investigators

Principal Investigator